You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,394,780


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,394,780
Title:Targeting PAX2 for the treatment of breast cancer
Abstract: The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
Inventor(s): Donald; Carlton D. (Mount Pleasant, SC)
Assignee: Phigenix, Inc. (Atlanta, GA)
Application Number:13/050,604
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,394,780
Patent Claims:1. A method for treating a breast condition in a subject, comprising: (a) determining a PAX2-to-DEFB1 expression ratio in breast tissue from said subject; (b) determining an estrogen receptor/progesterone receptor (ER/PR) status of said breast tissue from said subject; and (c) based on the results of (a) and (b), administering to a breast tissue of said subject, a composition that inhibits PAX2 expression or PAX2 activity, wherein said composition comprises one or more agents selected from the group consisting of a polynucleotide encoding an siRNA for PAX2, a polynucleotide that blocks binding of PAX2 to a DEFB1 promoter, an antagonist of angiotensin II, an antagonist of angiotensin II receptor, an antagonist of angiotensin-converting enzyme (ACE), an antagonist of mitogen-activated protein kinase (MEK), an antagonist of extracellular signal-regulated kinase 1,2 (ERK1,2), an antagonist of signal transducer and activator of transcription 3 (STAT3), and a blocker of the renin-angiotensin system (RAS) signaling pathway and wherein said composition that blocks the binding of PAX2 to the DEFB1 promoter comprises a polynucleotide comprising SEQ ID NO:1.

2. The method of claim 1, wherein said breast condition is breast cancer or MIN.

3. The method of claim 1, wherein said composition comprises a polynucleotide comprising SEQ ID NO:1 in forward or reverse orientation.

4. The method of claim 3, wherein said polynucleotide comprises the sequence of V-CCTTG-W, wherein each of V and W consist of a contiguous nucleotide sequence of 1 to 35 nucleotides that flank the CCTTG sequence of the DEFB1 promoter, and a complementary sequence thereof.

5. The method of claim 4, wherein said polynucleotide comprises a sequence selected from the group consisting of SEQ ID NOS: 16, 25 and 28.

6. The method of claim 1, wherein said composition is an anti-PAX2 agent conjugated to an antibody, a receptor or a ligand to target tumor tissue in said subject.

7. The method of claim 1, wherein step (c) further comprises administering a composition comprising an anti-hormonal agent.

8. The method of claim 7, wherein the anti-hormonal agent is Tamoxifen.

9. The method of claim 1, wherein step (c) further comprises administering a composition comprising an anti-ERBB-2/anti-Her-2 agent.

10. The method of claim 9, wherein the anti-ERBB-2/anti-Her-2 agent is Trastuzumab.

11. The method of claim 1, wherein step (c) further comprises administering a composition comprising an anti-AIB-1/SRC-3 agent.

12. The method of claim 1, wherein a compound that inhibits PAX2 expression or inhibits PAX2 activity is administered when the PAX2-to-DEFB1 expression ratio is elevated and the ER/PR status is ER.sup.+/PR.sup.+ or ER.sup.+/PR.sup.-.

13. A method for treating a breast condition in a subject, comprising administering to a breast tissue of the subject, a composition that inhibits PAX2 expression and/or PAX2 activity, wherein said composition comprises an anti-PAX2 siRNA.

Details for Patent 8,394,780

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2025-10-14
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2025-10-14
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 02/28/2019 ⤷  Try a Trial 2025-10-14
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.